ArticleMarine drugs2022
FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in
Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- An Alkaloid from MarinePharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Article
- DNMT1 modulation of RASSF1A methylation enhances breast cancer brain metastasis.Cell death & disease · 2025Article
- Timp2-modified gelatinhydroxyphenylpropionic acid hydrogels reverse enhanced scleral recovery and suppress myopia development in mice.Materials today. Bio · 2025Article
- PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression.Journal of pharmaceutical analysis · 2025Article
- Marine natural products as a source of novel anticancer drugs: an updated review (2019-2023).Natural products and bioprospecting · 2025Review
- FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis.Frontiers in pharmacology · 2025Article
- Protection of Tight Junctional Complexes between hCMEC/D3 Cells by Deep-Sea Fibrinolytic Compound FGFC1.Marine drugs · 2024Article
- Recent advancement of novel marine fungi derived secondary metabolite fibrinolytic compound FGFC in biomedical applications: a review.Frontiers in cellular and infection microbiology · 2024Review
- Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth.Cell death & disease · 2023Article
- Anticancer effects of marine compounds blocking the nuclear factor kappa B signaling pathway.Molecular biology reports · 2022Review
- A Novel Marine Pyran-Isoindolone Compound Enhances Fibrin Lysis Mediated by Single-Chain Urokinase-Type Plasminogen Activator.Marine drugs · 2022Article
- Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism.Marine drugs · 2022Review
- CircCRIM1 promotes nasopharyngeal carcinoma progression via the miR-34c-5p/FOSL1 axis.European journal of medical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
FGFC1, an active compound isolated from the culture of marine fungi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.